|本期目录/Table of Contents|

[1]杜春明,刘新垣.双基因溶瘤腺病毒OAd-mK5-shPKM2抗肝癌活性的初步探究[J].浙江理工大学学报,2019,41-42(自科一):106-112.
 DU Chunming,LIU Xinyuan.Antitumor effect of oncolytic adenovirus armed with mK5 and shPKM2 in liver cancer[J].Journal of Zhejiang Sci-Tech University,2019,41-42(自科一):106-112.
点击复制

双基因溶瘤腺病毒OAd-mK5-shPKM2抗肝癌活性的初步探究()
分享到:

浙江理工大学学报[ISSN:1673-3851/CN:33-1338/TS]

卷:
第41-42卷
期数:
2019年自科一期
页码:
106-112
栏目:
出版日期:
2018-12-15

文章信息/Info

Title:
Antitumor effect of oncolytic adenovirus armed with mK5 and shPKM2 in liver cancer
文章编号:
1673-3851 (2019) 01-0106-07
作者:
杜春明刘新垣
1.浙江理工大学生命科学学学院,杭州 310018;2.中国科学院上海生物化学与细胞生物学研究所,上海 200031
Author(s):
DU Chunming LIU Xinyuan
1.Collegeof Life Sciences, Zhejiang Sci-Tech University, Hangzhou 310018, China; 2.Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai 200031, China
关键词:
OAd-mK5-shPKM2肝癌抗癌基因生物治疗
分类号:
Q789
文献标志码:
A
摘要:
研究携带mK5和shPKM2的双基因溶瘤腺病毒(OAd-mK5-shPKM2)对肝癌细胞的体内和体外杀伤作用,通过PCR技术证明OAd-mK5-shPKM2中无野毒污染,Western blot检测腺病毒早期基因E1A和抗癌基因的表达,CCK8细胞增殖实验和动物实验检测溶瘤腺病毒对肝癌细胞的体外和体内杀伤作用。结果表明:OAd-mK5-shPKM2在细胞实验和动物实验中均可有效地抑制肝癌细胞的增殖,并且OAd-mK5-shPKM2对肝癌细胞增殖的抑制效果要强于单基因溶瘤腺病毒OAd-mK5或OAd-shPKM2。双基因溶瘤腺病毒OAd-mK5-shPKM2携带的两个基因可以共同促进溶瘤腺病毒对肝癌细胞的杀伤作用,为进一步研究恶性肿瘤的生物治疗提供理论依据。

参考文献/References:

[1] Rahib L, Smith B D, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States[J]. Cancer Research, 2014, 74(11):2913-2921.
[2] Ma B, Wang Y, Zhou X, et al. Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin[J]. Journal of Cancer Research and Clinical Oncology, 2015, 141(3):419-429.
[3] Hanahan D, Weinberg R A. Hallmarks of cancer: The next generation[J]. Cell, 2011, 14,(5):646-674.
[4] Wang Y, Huang F, Cai H, et al. Potent antitumor effect of TRAIL mediated by a novel adenoassociated viral vector targeting to telomerase activity for human hepatocellular carcinoma[J]. The Journal of Gene Medicine, 2008, 10(5):518-526.
[5] 郭婉,金槿,肖伯端,等. 基于溶瘤腺病毒抗肿瘤免疫治疗的前景与展望[J]. 中国细胞生物学学报, 2018, 40(6):1016-1022.
[6] Russell S J, Peng K W, Bell J C. Oncolytic virotherapy[J]. Nature Biotechnology, 2012, 30(7):658-670.
[7] Zhao L, Gu J, Zhang Y, et al. Potent antitumor activity of oncolytic adenovirus expressing mda7/IL24 for colorectal cancer[J]. Human Gene Therapy, 2005, 16(7):845-858.
[8] Liu X Y, Gu J F. Targeting genevirotherapy of cancer[J]. Cell Research, 2006, 16(1):25-30.
[9] 王世兵,孟树林,武虎,等. 双基因溶瘤腺病毒联合5FU抑制肺癌细胞增殖的研究[J]. 浙江理工大学学报, 2014, 31(4):445-450.

相似文献/References:

[1]周驰凯,潘强.6种化合物对肝癌细胞活性影响的比较[J].浙江理工大学学报,2015,33-34(自科2):249.
 ZHOU Chi kai,PAN Qiang.Comparison of Effects of Six Chemical Compounds on Activity of Liver Cancer Cell[J].Journal of Zhejiang Sci-Tech University,2015,33-34(自科一):249.
[2]孙笑竹,吕春伟,秦云,等.CDK抑制剂SNS 032联合AD55 Apoptin对肝癌细胞Huh 7的体外抗癌作用[J].浙江理工大学学报,2016,35-36(自科2):290.
 SUN Xiaozhu,L  Chunwei,QIN Yun,et al.In vitro Antitumor Effect of Combining CDK Inhibitor SNS 032  with AD55 Apoptin on Liver Carcinoma Cell Huh[J].Journal of Zhejiang Sci-Tech University,2016,35-36(自科一):290.
[3]郑娓诗,孙艺钦,赵雪芹,等.纳米明胶硅氧烷的制备及其负载p-53基因对肝癌抑制效果[J].浙江理工大学学报,2018,39-40(自科5):605.
 ZHENG Weishi,SUN Yiqin,ZHAO Xueqin,et al.Preparation of nanogelatin siloxane and inhibition effect of its loaded p53gene on the hepatocellular carcinoma[J].Journal of Zhejiang Sci-Tech University,2018,39-40(自科一):605.
[4]冯翠,赵瑞波,贾晓渊,等.间歇性禁食在裸鼠体内对肝癌进展的影响[J].浙江理工大学学报,2019,41-42(自科六):812.
 FENG Cuia,ZHAO Ruibob,JIA Xiaoyuana,et al.Effect of intermittent fasting on hepatocarcinoma progress in nude mice[J].Journal of Zhejiang Sci-Tech University,2019,41-42(自科一):812.

备注/Memo

备注/Memo:
收稿日期2018-06-02
网络出版日期:2018-11-02
基金项目:恩贝-浙理工“中美院士工作站”(116129A4J14365);国家自然科学基金项目(81372453,81572999)
作者简介:春明(1992-),男,河北承德人,硕士研究生,主要从事癌症的靶向基因-病毒治疗方面的研究。
通信作者:新垣,E-mail:xyliu@sibs.an.cn
更新日期/Last Update: 2019-03-13